Top Markets
Coin of the day
Adagio Therapeutics, Inc. Adagio Therapeutics, Inc.

Adagio Therapeutics, Inc.

ADGI
Ранг среди акций #16435
Adagio Therapeutics, Inc. is a clinical-stage biopharmaceutical firm, primarily... Adagio Therapeutics, Inc. is a clinical-stage biopharmaceutical firm, primarily focused on the discovery, development, and subsequent commercialization of antibody-based therapeutics designed to combat infectious diseases across the United States. Its most advanced product candidate, ADG20 (adintrevimab), is a neutralizing antibody currently undergoing Phase 3 clinical trials. This antibody is being evaluated for both the treatment and prevention of coronavirus disease. Adagio Therapeutics also engages in strategic collaborations. It partners with Adimab, LLC to facilitate the discovery and optimization of novel proprietary antibodies. Furthermore, the company works with the Scripps Research Institute on research initiatives aimed at identifying vaccine candidates that could prevent, diagnose, or treat influenza and beta coronaviruses. Founded in 2020, Adagio Therapeutics maintains its headquarters in Waltham, Massachusetts.
Цена акции
$4.64
Последняя синхронизация: 2022-09-12
Рыночная капитализация
$293.43M
Изменение (1 день)
0.87%
Изменение (1 год)
0.00%
Страна
US
Торговля Adagio Therapeutics, Inc. (ADGI)

Категория

Коэффициент P/B для Adagio Therapeutics, Inc. (ADGI)
Коэффициент P/B на 2026 TTM: 0
Согласно последним финансовым отчетам и цене акций Adagio Therapeutics, Inc., текущий коэффициент P/B (TTM) составляет 0. В конце 2026 он составлял 0.
История P/B для Adagio Therapeutics, Inc. с 2026 по 2026
Коэффициент P/B в конце каждого года
Год P/B Изменить
Недостаточно данных для указанных дат.
Коэффициент P/B для аналогичных компаний или конкурентов
Компания P/B Разница P/B Страна
6.828 -
US
7.5116 -
NL
8.2199 -
US
3.9942 -
AU
- -
CH